U.S. markets closed

Bausch Health Companies Inc. (BHC)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
6.28+0.27 (+4.49%)
At close: 04:00PM EDT
6.31 +0.03 (+0.48%)
After hours: 05:12PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close6.01
Bid6.30 x 900
Ask6.27 x 800
Day's Range5.90 - 6.31
52 Week Range4.00 - 29.59
Avg. Volume7,616,693
Market Cap2.277B
Beta (5Y Monthly)1.35
PE Ratio (TTM)44.86
EPS (TTM)0.14
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 10, 2010
1y Target Est15.18
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
79% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BHC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bausch Health Companies Inc.
    Analyst Report: Bausch Health Companies Inc.Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • Zacks

    Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision

    Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.

  • InvestorPlace

    7 Stock Price Predictions That Are Actually Worth Listening To

    Generally, Wall Street stock price predictions are hardly the best source of investing ideas that have the most upside. Investors should interpret stocks that analysts claim have the most upside carefully. Often, either the analyst is too optimistic about the company’s fair value or the stock market is wrong. Investors may pick stocks with the most promising price predictions by reviewing their stock scores. As difficult as it is to make stock price predictions based on the numbers alone, someti

  • CNW Group

    Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit

    Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, consistent with the company's July 28, 2022, press release, the U.S. District Court of Delaware has issued a decision in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. finding certain XIFAXAN® (rifaximin) 550 mg HE patents valid and infringed and certain XIFAXAN composition and IBS-D patents invalid. As previously stated, the Company will